Research Article
BibTex RIS Cite

Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes

Year 2024, Volume: 28 Issue: 5, 1665 - 1673, 28.06.2025

Refaa B Al-temimi Amer Hasan Abdulla Noor T Tahir

Abstract

Diabetic nephropathy (DN) is one of the most prevalent diabetic microvascular complications, affecting up to 40% of type 2 diabetic patients (T2DM) and represents a general reason of chronic kidney disorder and end-stage kidney disease (ESKD). This study aimed to evaluate the soluble alpha klotho and periostin (POSTN) role as predictor of diabetic- nephropathy (DN) on 120 patients, 60 with T2DM and 60 with DN under hemodialysis (DN-HD) in a cross-sectional study. Serum-soluble alpha-klotho and periostin levels were evaluated using ELISA techniques. Receiver operating characteristic curves were used to evaluate the predictive value of soluble alpha-klotho and periostin, which revealed that soluble alpha-klotho significantly decreased in DN-HD patients compared to T2DM patients, while periostin significantly increased in DN-HD patients in comparison with T2DM patients. Specificity and sensitivity of the soluble alpha klotho in predicting DN were (62% and 59%), at cut-off value was 98.63 ng/mL, while periostin’s sensitivity and specificity were (92% and 90%) at a cut-off value of 238.17 ng/mL which indicate that serum periostin can be considered as a valuable biomarker for early detection of DN in T2DM patients.

Keywords

Diabetic mellitus Diabetic-nephropathy soluble alpha klotho periostin

References

  • [1] Inci A, Sari F, Coban M, Olmaz R, Dolu S, Sarıkaya M, Yılmaz N. Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria. J Investig Med. 2016;64(6):1128-1133. https://doi.org/10.1136/jim-2016-000142
  • [2] Richter B, Faul C. FGF23 Actions on target tissues-with and without klotho. Front Endocrinol (Lausanne). 2018;9:189. https://doi.org/10.3389/fendo.2018.00189
  • [3] Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 2013;28(2):352-359. https://doi.org/10.1093/ndt/gfs460
  • [4] Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of Klotho. Semin Nephrol. 2013;33(2):118-129. https://doi.org/10.1016/j.semnephrol.2012.12.013
  • [5] Al-Jewari K, Baban R, and Manuti J. Serum and urinary soluble α-Klotho levels in patients with chronic kidney disease. Baghdad J Biochem Appl Biol Sci. 2021;2(01):29–38. https://doi.org/10.47419/bjbabs.v2i01.35
  • [6] Hanson K, Fisher K, Hooper NM. Exploiting the neuroprotective effects of α-klotho to tackle ageing- and neurodegeneration-related cognitive dysfunction. Neuronal Signal. 2021;5(2):NS20200101. https://doi.org/10.1042/ns20200101
  • [7] Landry T, Laing BT, Li P, Bunner W, Rao Z, Prete A, Sylvestri J, Huang H. Central α-klotho suppresses NPY/AgRP neuron activity and regulates metabolism in mice. Diabetes. 2020;69(7):1368-1381. https://doi.org/10.2337/db19-0941
  • [8] Espuch-Oliver A, Vázquez-Lorente H, Jurado-Fasoli L, de Haro-Muñoz T, Díaz-Alberola I, López-Velez MDS, de Haro-Romero T, Castillo MJ, Amaro-Gahete FJ. References values of soluble α-klotho serum levels using an enzyme-linked ımmunosorbent assay in healthy adults aged 18-85 years. J Clin Med. 2022;11(9):2415. https://doi.org/10.3390/jcm11092415
  • [9] Dalton GD, Xie J, An SW, Huang CL. New insights into the mechanism of action of soluble klotho. Front Endocrinol (Lausanne). 2017;8:323. https://doi.org/10.3389/fendo.2017.00323
  • [10] González-González L, Alonso J. Periostin: A matricellular protein with multiple functions in cancer development and progression. Front Oncol. 2018;8:225. https://doi.org/10.3389/fonc.2018.00225
  • [11] Kudo A. Introductory review: periostin-gene and protein structure. Cell Mol Life Sci. 2017;74(23):4259-4268. https://doi.org/10.1007/s00018-017-2643-5
  • [12] Dorafshan S, Razmi M, Safaei S, Gentilin E, Madjd Z, Ghods R. Periostin: biology and function in cancer. Cancer Cell Int. 2022;22(1):315. https://doi.org/10.1186/s12935-022-02714-8
  • [13] Turczyn A, Pańczyk-Tomaszewska M. The role of periostin in kidney diseases. Cent Eur J Immunol. 2021;46(4):494-501. https://doi.org/10.5114/ceji.2021.110317
  • [14] Abbad L, Prakoura N, Michon A, Chalghoumi R, Reichelt-Wurm S, Banas MC, Chatziantoniou C. Role of periostin and nuclear factor-κB ınterplay in the development of diabetic nephropathy. Cells. 2022;11(14):2212. https://doi.org/10.3390/cells11142212
  • [15] Yi HJ, Lee JB, Lee KP, Oh YI, Song KH, Seo KW. Investigation on urinary and serum alpha klotho in dogs with chronic kidney disease. BMC Vet Res. 2020;16(1):246. https://doi.org/10.1186/s12917-020-02458-5
  • [16] Liu QF, Yu LX, Feng JH, Sun Q, Li SS, Ye JM. The prognostic role of klotho in patients with chronic kidney disease: A systematic review and meta-analysis. Dis Markers. 2019;2019:6468729. https://doi.org/10.1155/2019/6468729
  • [17] Kawabata C, Komaba H, Ishida H, Nakagawa Y, Hamano N, Koizumi M, Kanai G, Wada T, Nakamura M, Fukagawa M. Changes in fibroblast growth factor 23 and soluble klotho levels after hemodialysis ınitiation. Kidney Med. 2019;2(1):59-67. https://doi.org/10.1016/j.xkme.2019.09.007
  • [18] Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, Sales S, Farcomeni A, Mazzaferro S. Soluble α-klotho serum levels in chronic kidney disease. Int J Endocrinol. 2015;2015:872193. https://doi.org/10.1155/2015/872193
  • [19] Hryszko T, Rydzewska-Rosołowska A, Goździkiewicz J, Brzósko S, Koc-Żórawska E, Zelazowska-Rutkowska B, Myśliwiec M. Cholecalciferol supplementation reduces soluble Klotho concentration in hemodialysis patients. Pol Arch Med Wewn. 2013;123(6):277-281. https://doi.org/10.20452/pamw.1768.
  • [20] Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, Iwazu K, Komada T, Otani N, Morishita Y, Ito C, Shiizaki K, Ando Y, Muto S, Kuro-o M, Kusano E. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012;13:155. https://doi.org/10.1186/1471-2369-13-155
  • [21] Tang A, Zhang Y, Wu L, Lin Y, Lv L, Zhao L, Xu B, Huang Y, Li M. Klotho's impact on diabetic nephropathy and its emerging connection to diabetic retinopathy. Front Endocrinol (Lausanne). 2023;14:1180169. https://doi.org/10.3389/fendo.2023.1180169
  • [22] Alesutan I, Henze LA, Boehme B, Luong TTD, Zickler D, Pieske B, Eckardt KU, Pasch A, Voelkl J. Periostin augments vascular smooth muscle cell calcification via β-catenin signaling. Biomolecules. 2022;12(8):1157. https://doi.org/10.3390/biom12081157
  • [23] Sen K, Lindenmeyer MT, Gaspert A, Eichinger F, Neusser MA, Kretzler M, Segerer S, Cohen CD. Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol. 2011;179(4):1756-1767. https://doi.org/10.1016%2Fj.ajpath.2011.06.002
  • [24] Guerrot D, Dussaule JC, Mael-Ainin M, Xu-Dubois YC, Rondeau E, Chatziantoniou C, Placier S. Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One. 2012;7(3):e31974. https://doi.org/10.1371/journal.pone.0031974
  • [25] Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, Yoshida NL, Maeda M, Pandit A, Lordan JL, Kamogawa Y, Arima K, Nagumo F, Sugimachi M, Berger A, Richards I, Roberds SL, Yamashita T, Kishi F, Kato H, Arai K, Ohshima K, Tadano J, Hamasaki N, Miyatake S, Sugita Y, Holgate ST, Izuhara K. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19(6):287-296. https://doi.org/10.1006/cyto.2002.1972
  • [26] Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010 ;107(32):14170-14175. https://doi.org/10.1073/pnas.1009426107
  • [27] Mael-Ainin M, Abed A, Conway SJ, Dussaule JC, Chatziantoniou C. Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol. 2014;25(8):1724-1736. https://doi.org/10.1681/asn.2013060664
  • [28] Schwanekamp JA, Lorts A, Vagnozzi RJ, Vanhoutte D, Molkentin JD. Deletion of periostin protects against atherosclerosis in mice by altering inflammation and extracellular matrix remodeling. Arterioscler Thromb Vasc Biol. 2016;36(1):60-68. https://doi.org/10.1161/atvbaha.115.306397
  • [29] Hakuno D, Kimura N, Yoshioka M, Mukai M, Kimura T, Okada Y, Yozu R, Shukunami C, Hiraki Y, Kudo A, Ogawa S, Fukuda K. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest. 2010;120(7):2292-2306. https://doi.org/10.1172/jci40973
  • [30] Foresto-Neto O, Albino AH, Arias SCA, Faustino VD, Zambom FFF, Cenedeze MA, Elias RM, Malheiros DMAC, Camara NOS, Fujihara CK, Zatz R. NF-κB System ıs chronically activated and promotes glomerular ınjury in experimental type 1 diabetic kidney disease. Front Physiol. 2020;11:84. https://doi.org/10.3389/fphys.2020.00084
  • [31] He X, Young SH, Schwegler-Berry D, Chisholm WP, Fernback JE, Ma Q. Multiwalled carbon nanotubes induce a fibrogenic response by stimulating reactive oxygen species production, activating NF-κB signaling, and promoting fibroblast-to-myofibroblast transformation. Chem Res Toxicol. 2011;24(12):2237-2248. https://doi.org/10.1021/tx200351d.
There are 31 citations in total.

Details

Primary Language English
Subjects Pharmaceutical Chemistry
Journal Section Articles
Authors

Refaa B Al-temimi 0009-0002-2227-4574

Amer Hasan Abdulla 0000-0001-6428-5197

Noor T Tahir 0000-0001-9518-6634

Publication Date June 28, 2025
Submission Date January 3, 2024
Acceptance Date January 23, 2024
Published in Issue Year 2024 Volume: 28 Issue: 5

Cite

APA B Al-temimi, R., Abdulla, A. H., & T Tahir, N. (2025). Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes. Journal of Research in Pharmacy, 28(5), 1665-1673.
AMA B Al-temimi R, Abdulla AH, T Tahir N. Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes. J. Res. Pharm. July 2025;28(5):1665-1673.
Chicago B Al-temimi, Refaa, Amer Hasan Abdulla, and Noor T Tahir. “Serum Soluble Alpha Klotho and Periostin As a Biomarker for Detection of Early Diabetic Nephropathy in Iraqi Male With Type 2 Diabetes”. Journal of Research in Pharmacy 28, no. 5 (July 2025): 1665-73.
EndNote B Al-temimi R, Abdulla AH, T Tahir N (July 1, 2025) Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes. Journal of Research in Pharmacy 28 5 1665–1673.
IEEE R. B Al-temimi, A. H. Abdulla, and N. T Tahir, “Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes”, J. Res. Pharm., vol. 28, no. 5, pp. 1665–1673, 2025.
ISNAD B Al-temimi, Refaa et al. “Serum Soluble Alpha Klotho and Periostin As a Biomarker for Detection of Early Diabetic Nephropathy in Iraqi Male With Type 2 Diabetes”. Journal of Research in Pharmacy 28/5 (July 2025), 1665-1673.
JAMA B Al-temimi R, Abdulla AH, T Tahir N. Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes. J. Res. Pharm. 2025;28:1665–1673.
MLA B Al-temimi, Refaa et al. “Serum Soluble Alpha Klotho and Periostin As a Biomarker for Detection of Early Diabetic Nephropathy in Iraqi Male With Type 2 Diabetes”. Journal of Research in Pharmacy, vol. 28, no. 5, 2025, pp. 1665-73.
Vancouver B Al-temimi R, Abdulla AH, T Tahir N. Serum soluble alpha klotho and periostin as a biomarker for detection of early diabetic nephropathy in Iraqi male with Type 2 Diabetes. J. Res. Pharm. 2025;28(5):1665-73.